Unilateral pain and shorter duration of chronic migraine are significant predictors of response to onabotulinumtoxin A

Eur J Neurol. 2018 Apr;25(4):e48. doi: 10.1111/ene.13570.

Authors

C Domínguez¹, P Pozo-Rosich², Y Leira³, R Leira¹

Affiliations

¹ Service of Neurology, Headache Unit, Hospital Clínico Universitario, University of Santiago de Compostela, Santiago de Compostela, Spain.
² Hospital Universitario Vall d'Hebron, Headache Research Group, Vall d'Hebron Institute of Research (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain.
³ OMEQUI Research Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.

PMID: 29575364
DOI: 10.1111/ene.13570

No abstract available

Keywords: chronic migraine; early treatment; effectiveness; onabotulinumtoxin A; predictors.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Botulinum Toxins, Type A*
Humans
Migraine Disorders*
Pain
Prospective Studies

Substances

Botulinum Toxins, Type A